An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease
Alzheimer’s disease is a condition that affects memory, thinking, and everyday tasks. This clinical trial is testing an experimental medicine called TML-6 to see if it can help people who are in the early stages of the condition. The main goal is to find out whether TML-6 is safe to take and if it can help protect memory and day-to-day thinking skills over 52 weeks (about one year). In this trial, participants are randomly chosen to take either TML-6 or an inactive dummy pill called a placebo. Neither the participants nor the research team will know who is taking which treatment. Throughout the study, doctors will closely monitor participants' health using routine memory checks, blood tests, and brain scans. The information gathered will help researchers understand whether TML-6 could become a helpful treatment for Alzheimer’s disease in the future.
At a glance
What is this study about?
Alzheimer’s disease develops gradually, often starting with mild memory slips before slowly making everyday activities more difficult. Today, researchers around the world are searching for new treatments that can slow down or pause this progression, particularly when caught early. This study is testing an investigational medicine called TML-6 to see how well it works and how safe it is for people in the early stages of Alzheimer’s.
During the trial, doctors want to measure whether TML-6 can help participants hold onto their thinking skills and independence. Over the course of 52 weeks, the research team will compare people taking TML-6 with people taking a placebo (a harmless pill that contains no active medicine). This comparison helps scientists prove whether any improvements or changes are genuinely caused by the new treatment.
Researchers will also look closely at biological signs of Alzheimer’s. They will use blood samples and specialised brain scans to measure specific proteins and track brain health. Finding out if a medicine can reduce these physical signs could open the door to better, more targeted treatments for dementia in the years ahead.
Key takeaways
- The trial tests a new drug called TML-6 for early Alzheimer's disease.
- The study lasts for 52 weeks (about one year).
- Half of the participants receive TML-6 and half receive an inactive placebo.
- Health checks, memory tests, blood samples, and brain scans will track safety and progress.
- Participation is entirely voluntary and does not replace your routine healthcare.
Who may be eligible?
This study is designed for adults who have been diagnosed with early Alzheimer’s disease or who are showing mild memory and thinking difficulties linked to the condition. Both men and women can take part.
To join, participants need to be well enough to attend regular clinic appointments and undergo standard medical tests, such as memory questionnaires, blood tests, and brain scans. Having a family member, friend, or carer who can attend visits and provide support is often very helpful.
Because this is a clinical trial, certain health conditions or existing medications might mean the study is not suitable for everyone. A study doctor will review each person's full medical history and current health before deciding if taking part is safe.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- You have a diagnosis of early Alzheimer’s disease or mild memory loss.
- You are willing to take the study treatment for 52 weeks.
- You can travel to regular study appointments at a clinic or hospital.
- You are comfortable having blood tests and lying still for brain scans.
- You have a study partner, carer, or family member who can help support your visits.
What does participation involve?
Taking part in this study lasts for about 52 weeks (one year). During this time, participants will be randomly assigned to take either TML-6 or a placebo. You will have regular visits to a study clinic where doctors will check your general health, blood pressure, weight, and mood. You will also complete memory and thinking assessments, give routine blood samples, and have brain scans (such as an MRI scan and, at some clinics, a PET scan) to monitor your brain. If you ever feel unwell or have questions, the clinic team will be available to support you throughout the year.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What is a placebo and why is it used?
A placebo is a pill that looks identical to the real medicine but contains no active ingredients. It is used so doctors can see whether changes in health are really caused by the medicine rather than other factors.
Will I know if I am taking TML-6 or the placebo?
No. To keep the results fair and unbiased, neither you nor your study doctors will know which treatment you are receiving until the study is finished.
How long does the study last?
The study lasts for 52 weeks, which is about one full year of treatment and monitoring.
Can I leave the trial if I change my mind?
Yes. You have the right to withdraw from the trial at any point, for any reason, without giving an explanation.
Will taking part affect my usual NHS treatment?
No. Your normal NHS healthcare team will continue to look after you, and leaving or joining the study will not harm your standard care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.